<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056589</url>
  </required_header>
  <id_info>
    <org_study_id>F13-1663</org_study_id>
    <nct_id>NCT00056589</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency</brief_title>
  <official_title>A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was conducted in the United States of America (USA). The aim of this trial was to&#xD;
      investigate safety and pharmacokinetics of escalating single doses of catridecacog&#xD;
      (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Days 0-28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline in physical examination or laboratory measurements</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rFXIII antibodies, as measured by ELISA (Enzyme-Linked Immuno Sorbent Assay)</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of yeast antibodies</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXIII activity measured by the BerichromÂ® assay</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Congenital FXIII Deficiency</condition>
  <arm_group>
    <arm_group_label>rFXIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>catridecacog</intervention_name>
    <description>Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).</description>
    <arm_group_label>rFXIII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documental congenital FXIII deficiency&#xD;
&#xD;
          -  Normal platelet count and clotting parameters&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  If female and of child-bearing potential, negative serum pregnancy test within 7 days&#xD;
             of enrollment&#xD;
&#xD;
          -  If a sexually active male or a sexually active female of child-bearing potential,&#xD;
             agreement to use a medically accepted form of contraception from the time of&#xD;
             enrollment to completion of all follow-up study visits&#xD;
&#xD;
          -  Negative drug and alcohol screens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received blood products or FXIII concentrates within 4 weeks of study enrollment&#xD;
&#xD;
          -  Known antibodies to FXIII&#xD;
&#xD;
          -  Hereditary or acquired coagulation disorder other than FXIII deficiency&#xD;
&#xD;
          -  Previous history of autoimmune disorders involving autoantibodies e.g., systemic lupus&#xD;
             erythematosus&#xD;
&#xD;
          -  Previous history of thromboembolic events e.g., cerebrovascular accident or deep vein&#xD;
             thrombosis or administration of any antithrombotic or antiplatelet drugs within 7 days&#xD;
             of study enrollment&#xD;
&#xD;
          -  Received treatment with any experimental agent within 30 days of study enrollment&#xD;
&#xD;
          -  Any surgical procedure in the 30 days prior to enrollment&#xD;
&#xD;
          -  Donated blood within 30 days prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 1;108(1):57-62. Epub 2006 Mar 23.</citation>
    <PMID>16556896</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 18, 2003</study_first_submitted>
  <study_first_submitted_qc>March 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2003</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

